FGFR3 mutation analysis in voided urine samples to decrease cystoscopies and cost in nonmuscle invasive bladder cancer surveillance: a comparison of 3 strategies
van Kessel KE, Kompier LC, de Bekker-Grob EW, Zuiverloon TC, Vergouwe Y, Zwarthoff EC, Steyerberg EW

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

DOI
10.1016/j.juro.2012.11.005

Indexing Status
Subject indexing assigned by NLM

MeSH
Adult; Aged; Aged, 80 and over; Carcinoma, Transitional Cell /diagnosis /economics /genetics /urine; Cost-Benefit Analysis; Cystoscopy /statistics & numerical data; Female; Humans; Male; Middle Aged; Receptor, Fibroblast Growth Factor, Type 3 /genetics; Retrospective Studies; Urinary Bladder Neoplasms /diagnosis /economics /genetics /urine

AccessionNumber
22013019083

Date bibliographic record published
17/06/2013